Published in Front Cell Dev Biol on August 22, 2016
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04
A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature (2005) 5.75
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell (2000) 5.72
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene (1995) 4.10
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res (2005) 3.78
Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res (2009) 3.70
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol (2005) 3.48
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 3.37
Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 3.37
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol (1995) 3.09
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J (1995) 2.87
A dimerization motif for transmembrane alpha-helices. Nat Struct Biol (1994) 2.82
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res (2011) 2.74
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron (2007) 2.54
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem (2000) 2.46
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature (2013) 2.33
The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem (2001) 2.25
Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol (1994) 2.20
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol (2014) 2.14
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol (1999) 2.03
ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem (1999) 1.98
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97
The basic biology of HER2. Ann Oncol (2001) 1.97
Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol (2007) 1.96
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res (2010) 1.94
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal (2013) 1.92
Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell (1999) 1.74
Ligand-induced ErbB receptor dimerization. Exp Cell Res (2008) 1.73
Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem (2006) 1.70
Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol (2001) 1.67
Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat (1995) 1.63
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.58
Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med (2012) 1.57
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther (2012) 1.53
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal (2014) 1.49
Role of HER receptors family in development and differentiation. J Cell Physiol (2004) 1.44
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
ErbBs in mammary development. Exp Cell Res (2003) 1.38
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol (2015) 1.37
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res (2008) 1.30
Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol (1998) 1.30
A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev (2013) 1.21
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene (2012) 1.20
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem (2003) 1.18
Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J Biol Chem (2004) 1.14
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol (2010) 1.13
Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene (2001) 1.12
EGFR/Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal (2010) 1.11
PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol (2009) 1.04
A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem (2015) 1.04
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer (2011) 1.03
Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains. J Mol Biol (2009) 1.03
c-erbB-4/HER4: friend or foe? J Pathol (2003) 1.00
The Mysterious Ways of ErbB2/HER2 Trafficking. Membranes (Basel) (2014) 0.96
ErbB-4 activation inhibits apoptosis in PC12 cells. Neuroscience (2001) 0.95
Heregulins and the ErbB-2/3/4 receptors in gliomas. J Neurooncol (1997) 0.92
Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF. J Biol Chem (2001) 0.92
A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell (2004) 0.91
Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem (2000) 0.91
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther (2013) 0.91
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget (2015) 0.90
Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer (2014) 0.88
Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene (1996) 0.88
Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. J Biol Chem (2013) 0.87
The epidermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor beta receptor. J Biol Chem (1998) 0.87
Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev (2015) 0.85
Evidence for new homotypic and heterotypic interactions between transmembrane helices of proteins involved in receptor tyrosine kinase and neuropilin signaling. J Mol Biol (2014) 0.85
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Biochem Soc Trans (2014) 0.85
Activating ERBB4 mutations in non-small cell lung cancer. Oncogene (2015) 0.84
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. Onco Targets Ther (2016) 0.83
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther (2016) 0.82
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. Clin Med Insights Oncol (2016) 0.82
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs (2015) 0.82
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother (2015) 0.81
The HER3/ErbB3 receptor: a promising target in cancer drug therapy. Gastroenterol Clin Biol (2010) 0.80
Lapatinib. Recent Results Cancer Res (2014) 0.80
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers. Sci Signal (2016) 0.80
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget (2016) 0.78
Managing acquired resistance in EGFR-mutated non-small cell lung cancer. Clin Adv Hematol Oncol (2015) 0.78